Inventiva S.A. (NASDAQ:IVA – Free Report) – HC Wainwright decreased their FY2023 earnings per share (EPS) estimates for Inventiva in a research note issued to investors on Monday, October 2nd. HC Wainwright analyst E. Arce now anticipates that the company will post earnings per share of ($2.32) for the year, down from their prior forecast of ($2.06). HC Wainwright has a “Buy” rating and a $35.00 price objective on the stock. The consensus estimate for Inventiva’s current full-year earnings is ($2.02) per share. HC Wainwright also issued estimates for Inventiva’s FY2024 earnings at ($2.34) EPS, FY2025 earnings at ($2.81) EPS, FY2026 earnings at ($2.34) EPS and FY2027 earnings at $2.82 EPS.
IVA has been the subject of several other research reports. Roth Mkm reaffirmed a “buy” rating and set a $11.00 price target on shares of Inventiva in a research note on Thursday, September 21st. Guggenheim reissued a “buy” rating and issued a $12.00 target price on shares of Inventiva in a research note on Friday, September 1st. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Inventiva has a consensus rating of “Buy” and a consensus price target of $19.33.
Inventiva Price Performance
NASDAQ:IVA opened at $4.10 on Thursday. The business has a fifty day simple moving average of $3.85 and a two-hundred day simple moving average of $3.64. Inventiva has a 1 year low of $2.22 and a 1 year high of $11.75.
Institutional Investors Weigh In On Inventiva
Institutional investors and hedge funds have recently bought and sold shares of the business. Morgan Stanley raised its position in shares of Inventiva by 300.0% in the 4th quarter. Morgan Stanley now owns 6,000 shares of the company’s stock worth $27,000 after acquiring an additional 4,500 shares in the last quarter. OLD Mission Capital LLC bought a new stake in shares of Inventiva in the 4th quarter worth $25,000. Citigroup Inc. increased its holdings in shares of Inventiva by 91.7% in the 1st quarter. Citigroup Inc. now owns 23,000 shares of the company’s stock worth $84,000 after purchasing an additional 11,000 shares in the last quarter. Finally, Commonwealth Equity Services LLC purchased a new position in shares of Inventiva in the 1st quarter worth $51,000. Hedge funds and other institutional investors own 11.46% of the company’s stock.
Inventiva Company Profile
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease.
See Also
- Five stocks we like better than Inventiva
- How to Buy Cheap Stocks Step by Step
- Huawei Has Entered The Chips Race, Markets Still Prefer These
- What Does the Consumer Price Index Measure?
- Restaurant Stocks Go on Sale…Which Are Really on the Value Menu?
- 3 Monster Growth Stocks to Buy Now
- 5 Reasons to Buy and Hold Exxon Mobil For 2024
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
